Gorde:
| Egile nagusia: | |
|---|---|
| Formatua: | Recurso digital |
| Hizkuntza: | |
| Argitaratua: |
Zenodo
2025
|
| Gaiak: | |
| Sarrera elektronikoa: | https://doi.org/10.5281/zenodo.17823410 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|
Aurkibidea:
- Multiple proprietary treatments are available for NSCLC, targeting specific genetic mutations with varying recent licensing dates. These treatments include selpercatinib, pembrolizumab, osimertinib, alectinib, anlotinib, and durvalumab, among others.